Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phytostanol tablets reduce human LDL-cholesterol.

Timothy B McPherson1, Richard E Ostlund, Anne C Goldberg

  • 1St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO 63110, USA.

The Journal of Pharmacy and Pharmacology
|June 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Commentary on reduction of major adverse cardiovascular events in primary prevention trials (meta-analysis by Kalra et al.).

Journal of clinical lipidology·2026
Same author

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association.

Journal of clinical lipidology·2026
Same author

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.

The New England journal of medicine·2025
Same journal

Uterine relaxant effects of Ageratum conyzoides essential oil: influence of hormonal status and calcium modulation.

The Journal of pharmacy and pharmacology·2026
Same journal

Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.

The Journal of pharmacy and pharmacology·2026
Same journal

Exploring the mechanism of action of Qufengzhitong pills in treating rheumatoid arthritis via the PI3K/AKT, NF-κB, and MAPK pathways.

The Journal of pharmacy and pharmacology·2026
Same journal

Mechanistic evidence for PI3K/Akt-driven reactivation of Nrf2/HO-1 by dapagliflozin in acute cisplatin hepatotoxicity.

The Journal of pharmacy and pharmacology·2026
Same journal

Advances in nano-drug delivery systems for targeting therapy of breast cancer.

The Journal of pharmacy and pharmacology·2026
Same journal

Zi Shen decoction inhibits non-small cell lung cancer progression by regulating macrophage polarization via the gut microbiota.

The Journal of pharmacy and pharmacology·2026
See all related articles

Solid dosage forms with stanol lecithin can lower LDL-cholesterol. Rapidly disintegrating tablets were effective, while slow-release capsules were not, highlighting the importance of delivery form for cholesterol absorption.

Area of Science:

  • Nutritional Science
  • Pharmacology
  • Biochemistry

Background:

  • Elevated LDL-cholesterol is a significant risk factor for cardiovascular disease.
  • Stanol lecithin has shown potential for cholesterol-lowering effects.
  • Optimizing the delivery of stanols is crucial for maximizing their efficacy.

Purpose of the Study:

  • To investigate the feasibility of solid dosage forms containing stanol lecithin for lowering LDL-cholesterol.
  • To evaluate the impact of different disintegration times on the cholesterol-lowering activity of stanol lecithin formulations.
  • To determine the optimal delivery system for stanol lecithin to enhance its LDL-cholesterol reduction potential.

Main Methods:

  • Investigated particle size distribution of stanol lecithin dispersions at various weight ratios.

Related Experiment Videos

  • Developed spray-dried stanol lecithin preparations and reconstituted them into solid dosage forms (tablets and capsules) with differing disintegration times.
  • Conducted a placebo-controlled, double-blind clinical trial with 52 subjects to assess LDL-cholesterol reduction activity.

    • Main Results:

    • Stanol-to-lecithin weight ratios of 1.00-1.50 allowed for successful spray drying and reconstitution.
    • Rapidly disintegrating tablets (disintegration time < 10 min) containing 1.26 g stanols daily led to a statistically significant decrease in LDL-cholesterol (10.4%) and LDL/HDL ratio (11.5%) compared to placebo.
    • Slowly disintegrating capsules (disintegration time > 45 min) with 1.01 g stanols daily showed no significant difference in lipid parameters compared to placebo.

    Conclusions:

    • The efficacy of stanol lecithin in reducing LDL-cholesterol is highly dependent on its delivery form.
    • Rapidly dispersible solid dosage forms are essential for stanol lecithin to effectively reach the site of cholesterol absorption and exert its cholesterol-lowering effects.
    • These findings underscore the importance of formulation design in optimizing the therapeutic potential of dietary supplements for lipid management.